Eikon Therapeutics, Inc. 8-K

What Happened
Eikon Therapeutics, Inc. filed a Current Report on Form 8‑K (filed June 1, 2026) disclosing two items: an updated corporate presentation (furnished May 30, 2026) and a press release issued May 30, 2026 announcing new and updated clinical data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The clinical updates cover EIK1001 (Phase 2 in first‑line patients with stage 4 non‑small cell lung cancer) and EIK1003 (new and updated data from the Phase 1/2 program in patients with advanced solid tumors). The presentation is included as Exhibit 99.1 and the press release as Exhibit 99.2 to the 8‑K.

Key Details

• Date of announcements: May 30, 2026; Form 8‑K filed June 1, 2026.
• Corporate presentation updated and furnished as Exhibit 99.1.
• Press release with ASCO data furnished as Exhibit 99.2.
• Clinical programs referenced: EIK1001 (Phase 2, first‑line stage 4 NSCLC) and EIK1003 (Phase 1/2, advanced solid tumors).

Why It Matters
Clinical data presented at ASCO can materially affect a biotech company's development outlook and investor expectations. This 8‑K signals that Eikon has new/updated efficacy and/or safety information for two pipeline assets; investors should review the attached presentation and press release for the specific trial results, enrollment/status details, and any implications for timelines or next steps. The filing does not report financial results or corporate transactions.